NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Beovu shows promise in Real-World eye disease study
Disease control CompletedThis study looked at how well the drug Beovu (brolucizumab) works in everyday medical practice for people with two eye diseases: wet age-related macular degeneration and diabetic macular edema. Researchers followed 572 patients who were already prescribed Beovu by their doctor, t…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 07:25 UTC
-
Fewer shots, same sight? study tests 3-Loading-Dose strategy for wet AMD
Disease control CompletedThis study looked at whether three monthly loading doses of the drug faricimab can effectively control wet age-related macular degeneration (AMD), a leading cause of vision loss in older adults. Researchers followed 742 patients who had not been treated before to see how long the…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated May 22, 2026 13:52 UTC